glp 1 review article GLP-1-based therapies for diabetes, obesity and beyond Glucagon-like peptide-1 receptor: mechanisms and

Ongoing trials will determine if liraglutide (41), lixisenatide (ELIXIRS trial) (42) and semaglutide (FLOW trial) (43) reduce dialysis rates and reduce worsening kidney function in people with diabetic kidney disease

It also has a longer half-life, meaning it stays active in the body for a longer period, which leads to more sustained appetite suppression and better blood sugar control

The FLOW trial was a major step in this area

In Australia, you can obtain a free sharps container from most pharmacies

Instead, you should opt for nutrient-dense options such as fresh fruits, vegetables, lean proteins, and whole grains